Skip to main content

Advertisement

SpringerLink
Log in

A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478

    Article  PubMed  CAS  Google Scholar 

  2. van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21(4):589–624

    Article  PubMed  Google Scholar 

  3. Guth U et al (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428–433

    Article  PubMed  CAS  Google Scholar 

  4. Guth U et al (2011) Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: How often and how often does it work? Breast Cancer Res Treat 129(3):799–807

    Article  PubMed  Google Scholar 

  5. Rae JM et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9(4):258–264

    Article  PubMed  CAS  Google Scholar 

  6. Ishak KJ et al (2007) Meta-analysis of longitudinal studies. Clin Trials 4(5):525–539

    Article  PubMed  Google Scholar 

  7. Klein JP et al (2007) Analyzing survival curves at a fixed point in time. Stat Med 26(24):4505–4519

    Article  PubMed  Google Scholar 

  8. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48

    Google Scholar 

  9. McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768

    Article  PubMed  CAS  Google Scholar 

  10. Partridge AH et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562

    Article  PubMed  CAS  Google Scholar 

  11. Kimmick G et al (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445–3451

    Article  PubMed  Google Scholar 

  12. Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128

    Article  PubMed  Google Scholar 

  13. Neugut AI et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29(18):2534–2542

    Article  PubMed  Google Scholar 

  14. Nekhlyudov L et al (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689

    Article  PubMed  CAS  Google Scholar 

  15. Huiart L, Dell’Aniello S, Suissa S (2011) Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104(10):1558–1563

    Article  PubMed  CAS  Google Scholar 

  16. Huiart L et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946

    Article  PubMed  Google Scholar 

  17. Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2012) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. doi:10.1097/coc.0b013e3182436ec1

  18. Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606

    Article  PubMed  CAS  Google Scholar 

  19. Grunfeld EA et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97–102

    Article  PubMed  Google Scholar 

  20. Ma AM et al (2008) Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 196(4):500–504

    Article  PubMed  Google Scholar 

  21. Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H (2009) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in earlystage breast cancer. J Clin Oncol 28(14):2423–2429

    Google Scholar 

  22. Ziller V et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431–436

    Article  PubMed  CAS  Google Scholar 

  23. Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125(1):191–200

    Article  PubMed  CAS  Google Scholar 

  24. Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 1(4):E1–E21. doi:10.5600/mmrr.001.04.a04

    Google Scholar 

  25. Thompson AM et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279–287

    Article  PubMed  CAS  Google Scholar 

  26. Wigertz A et al (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373

    Article  PubMed  CAS  Google Scholar 

  27. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328

    PubMed  CAS  Google Scholar 

  28. Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315

    Article  PubMed  Google Scholar 

  29. Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220

    Article  PubMed  Google Scholar 

  30. Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439

    Article  PubMed  Google Scholar 

  31. Owusu C et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4):549–555

    Article  PubMed  Google Scholar 

  32. Schwartzberg LS et al (2009) Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast 18(2):78–83

    Article  PubMed  Google Scholar 

  33. van Herk-Sukel MP et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851

    Article  PubMed  Google Scholar 

  34. Dittmer C et al (2011) Compliance to adjuvant therapy in breast cancer patients. Eur J Gynaecol Oncol 32(3):280–282

    PubMed  CAS  Google Scholar 

References for Rebuttal letter

  1. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478

    Article  PubMed  CAS  Google Scholar 

  2. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. (2012) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: a randomised trial. Lancet

  3. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102

    Article  PubMed  Google Scholar 

  4. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315

    Article  PubMed  Google Scholar 

  5. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439

    Article  PubMed  Google Scholar 

  6. Huiart L, Bouknik A, Rey D, Tarpin C, Cluze C, Bendiane MK, Viens P, Giorgi R (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are indebted to Arianne Dorval for proofreading the English manuscript.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Unité de Soutien Méthodologique, CHU La Réunion—CHFG, Allées Topaze, 97400, Saint-Denis, France

    Laetitia Huiart & Cyril Ferdynus

  2. INSERM, U912 (SESSTIM), Marseille, France

    Laetitia Huiart & Roch Giorgi

  3. Université Aix Marseille, IRD, UMR-S912, Marseille, France

    Laetitia Huiart & Roch Giorgi

  4. Service de Santé Publique et d’Information Médicale, Hôpital de la Timone, Assistance Publique—Hôpitaux de Marseille, 264 rue St Pierre, 13385, Marseille Cedex, France

    Roch Giorgi

Authors
  1. Laetitia Huiart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyril Ferdynus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roch Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laetitia Huiart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huiart, L., Ferdynus, C. & Giorgi, R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138, 325–328 (2013). https://doi.org/10.1007/s10549-013-2422-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2422-4

Keywords

Search

Navigation